Arvinas to Present New Phase 3 and Phase 2 Vepdegestrant Clinical Trial Data at 2025 ESMO Congress
I'm PortAI, I can summarize articles.
Arvinas Inc. will present new data from its vepdegestrant clinical trials at the 2025 ESMO Congress in Berlin, scheduled for October 17-21, 2025. The investigational drug, developed with Pfizer, targets ER+/HER2- advanced breast cancer. Presentations will include patient-reported outcomes from the Phase 3 VERITAC-2 trial and results from the Phase 2 TACTIVE-N study. This information has not been previously disclosed and will be shared at the congress.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments